PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

UK trial to evaluate existing drugs for secondary breast cancer

A new UK-based clinical trial will evaluate existing cancer drugs as potential treatments for women living with metastatic breast cancer. The study, led by Profes...
Continue Reading →
News

AstraZeneca invests in Imperial College spin-off VaxEquity

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA...
Continue Reading →
News

Positive Phase III results for Lynparza plus abiraterone in metastatic prostate cancer

Positive high-level results from the PROpel Phase III trial have shown that AstraZeneca and MSD’s Lynparza (olaparib), in combination with abiraterone, dem...
Continue Reading →
News

New report sheds light on medicine shortages in Northern Ireland following Brexit

Informa Pharma Intelligence (IPI) has found that some drug firms may withdraw up to 90% of their products from Northern Ireland, once the Brexit grace period has pas...
Continue Reading →
News

FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) for the treatment of patients with previously treated radioactive iodine-re...
Continue Reading →
News

Mirati’s adagrasib scores encouraging results in KRAS-mutated lung cancer

US biotech company Mirati Therapeutics announced positive Phase II results for its investigational treatment adagrasib as a treatment for KRAS-mutated lung cancer. ...
Continue Reading →
News

Positive topline results for Pfizer/BioNTech jab in five to 11-year-olds

Pfizer and BioNTech have announced that their COVID-19 vaccine is safe for use in children aged five to 11 years old. Results from a Phase II/III trial showed a f...
Continue Reading →
News

Promising early results for new ovarian cancer drug combo

Results from an early-stage clinical trial found a new combination of target drugs could provide a new treatment option for treatment-resistant advanced ovarian canc...
Continue Reading →
News

Sanofi/Regeneron’s Libtayo hits the mark in first-line NSCLC

Sanofi and Regeneron have announced positive late-stage results for Libtayo (cemiplimab) plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC) at...
Continue Reading →
News

Pharmapack Report 2021: US leads on drug device innovation but trails Europe on sustainability

Event agenda to track trends in sustainability, patient-centered device design and biosimilars and autoinjectors Ahead of the first Pharmapack Europe to...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026